Chan Kyu Kim

Prof. Dr. Chan Kyu Kim

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HKHyun Jung Kim
Hyun Jung Kim
JYJina Yun
Jina Yun
HKHan Jo Kim
Han Jo Kim
KKKyoung Ha Kim
Kyoung Ha Kim
SKSe Hyung Kim
Se Hyung Kim
DHDae Sik Hong
Dae Sik Hong
Kim HJ, et al. J Korean Med Sci. 2010 Dec;25(12):1748-1753. http://dx.doi.org/10.3346/jkms.2010.25.12.1748

1 January 2012 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HKHyun Jung Kim
Hyun Jung Kim
HKHan Jo Kim
Han Jo Kim
JYJina Yun
Jina Yun
KKKyoung Ha Kim
Kyoung Ha Kim
SKSe Hyung Kim
Se Hyung Kim
DHDae Sik Hong
Dae Sik Hong
Kim HJ, et al. J Korean Med Sci. 2012 Feb;27(2):128-134. http://dx.doi.org/10.3346/jkms.2012.27.2.128

1 December 2011 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JKJi Yeon Kwon
Ji Yeon Kwon
JYJina Yun
Jina Yun
HKHan Jo Kim
Han Jo Kim
KKKyoung-Ha Kim
Kyoung-Ha Kim
SKSe-Hyung Kim
Se-Hyung Kim
HPHee Sook Park
Hee Sook Park
Kwon JY, et al. Cancer Res Treat. 2011 Dec;43(4):244-249. http://dx.doi.org/10.4143/crt.2011.43.4.244

1 May 2006 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JWJong-Ho Won
Jong-Ho Won
SHSeung-Hyo Han
Seung-Hyo Han
SBSang-Byung Bae
Sang-Byung Bae
CKChan Kyu Kim
Chan Kyu Kim
NLNam-Su Lee
Nam-Su Lee
HPHee-Sook Park
Hee-Sook Park
Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonim-munosuppressed patients. Patients present with lymphomatous effusions in serous cavities—pleura, pericardium, or peritoneum–without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.

30 March 2004 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SPSoo Jin Park
Soo Jin Park
HKHyun Kun Kim
Hyun Kun Kim
CKChan Kyu Kim
Chan Kyu Kim
SPSung Kyu Park
Sung Kyu Park
EGEun Suk Go
Eun Suk Go
DHDae Sik Hong
Dae Sik Hong
We experienced a case of primary renal synovial sarcoma in a 32 year-old woman. On admission, she complained of intermittent abdominal pain. On radiologic examination, a 12 x 10 cm-sized soft tissue mass was detected on the left kidney. The tumor had histologic and immunophenotypic features that were consistent with spindle cell type monophasic synovial sarcoma. Four months after complete resection of the tumor, a unilateral hematogenous metastasis developed in the lung. She was treated with combined chemotherapy of doxorubicin and ifosfamide every four weeks, and complete remission was achieved. We herein describe the case with a brief review.

1 August 2013 in Stem Cell Reports
Verified
Journal Article
Open access
FLFang Liu
Fang Liu
SBSuk Ho Bhang
Suk Ho Bhang
EAElizabeth Arentson
Elizabeth Arentson
ASAtsushi Sawada
Atsushi Sawada
CKChan Kyu Kim
Chan Kyu Kim
KCKyunghee Choi
Kyunghee Choi
The fetal liver kinase 1 (FLK-1)(+) hemangioblast can generate hematopoietic, endothelial, and smooth muscle cells (SMCs). ER71/ETV2, GATA2, and SCL form a core transcriptional network in hemangioblast development. Transient coexpression of these three factors during mesoderm formation stage in mouse embryonic stem cells (ESCs) robustly enhanced hemangioblast generation by activating bone morphogenetic protein (BMP) and FLK-1 signaling while inhibiting phosphatidylinositol 3-kinase, WNT signaling, and cardiac output. Moreover, etsrp, gata2, and scl inhibition converted hematopoietic field of the zebrafish anterior lateral plate mesoderm to cardiac. FLK-1(+) hemangioblasts generated by transient coexpression of the three factors (ER71-GATA2-SCL [EGS]-induced FLK-1(+)) effectively produced hematopoietic, endothelial, and SMCs in culture and in vivo. Importantly, EGS-induced FLK-1(+) hemangioblasts, when codelivered with mesenchymal stem cells as spheroids, were protected from apoptosis and generated functional endothelial cells and SMCs in ischemic mouse hindlimbs, resulting in improved blood perfusion and limb salvage. ESC-derived, EGS-induced FLK-1(+) hemangioblasts could provide an attractive cell source for future hematopoietic and vascular repair and regeneration.